FeesSafety
Pluang+

Ethereum's stablecoin supply share hits record low at 46% as market shifts to Tron and others.

Market News
11 Nov 2026, 23:25 WIB
Tokenpost
View Source
Neutral
Ethereum's stablecoin supply share hits record low at 46% as market shifts to Tron and others.

Ethereum's share of stablecoin supply across blockchain networks dropped to a record low of 46%, with its on-chain stablecoin supply declining by $32.5 billion over the past year. Meanwhile, the total stablecoin supply across the market fell by about $10 billion. Tron gained $16.2 billion in stablecoin supply, reaching 32% market share, while newer networks like Hyperliquid, Solana, and several launched this year (Arc, X Layer, Robinhood Chain, Tempo, Monad) collectively added $8.4 billion. This shift highlights growing diversification in stablecoin issuance across different blockchain platforms.

Ethereum stablecoin market share shifts provide context for cryptocurrency trends. For readers following crypto markets, here is Pluang's snapshot as of Nov 12, 2026 04:22 WIB: Out of 50 major cryptocurrencies priced on Pluang, 31 rose and 18 fell today. Notable moves include SXP (Solar) down 46.27% to Rp37 with a typical hold time of 94 days, ONE (Harmony) down 18.24% to Rp27 with 41% sell and 59% buy order activity and a typical hold time of 153 days, and BAL (Balancer) up 11.14% to Rp16.297 with a typical hold time of 85 days.

More News

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...

Market News
Bullish
3 hours ago
Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...

Bullish
3 hours ago
Vylor reports mixed Q3 2026 results, confirms 2026 guidance, and launches $3B share buyback plus dividend.

Vylor reports mixed Q3 2026 results, confirms 2026 guidance, and launches $3B share buyback plus dividend.

Vylor, Inc. announced its Q3 2026 financial results showing a slight decline in net sales and increased losses compared to last year, mainly due to volume decreases from weather and market shifts. Despite this, the company saw strong demand for its h...

Company Fundamentals
Bullish
5 hours ago
Castle Biosciences to present company overview at Piper Sandler Healthcare Conference on Dec 2, 2026

Castle Biosciences to present company overview at Piper Sandler Healthcare Conference on Dec 2, 2026

Castle Biosciences, a diagnostics company specializing in tests for dermatologic and gastroenterological diseases, announced its executive management will present a company overview at the Piper Sandler 38th Annual Healthcare Conference on December 2...

Market News
Neutral
5 hours ago
Octave acquires Cerebre to enhance industrial AI with connected plant models for better facility management.

Octave acquires Cerebre to enhance industrial AI with connected plant models for better facility management.

Octave Intelligence plc has acquired Cerebre, a U.S.-based software firm that creates connected plant models by integrating engineering schematics and plant data. This acquisition aims to strengthen Octave's industrial AI capabilities, especially for...

Company Fundamentals
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App